Role of the transcription factor Ikaros in development of autoimmune disease
Role of the transcription factor Ikaros in development of autoimmune disease
批准号:
10408036
负责人:
Seth E Frietze
金额:
$39.54万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-15 至 2023-05-31
关键词:
AffectAgeAmericanAntibodiesAntigensAntinuclear AntibodiesAutoantibodiesAutoimmuneAutoimmune DiseasesAutoimmune ProcessAutoimmunityB-Cell ActivationB-LymphocytesBiological AssayCell LineageCell MaturationCellsChronicDNA BindingDataDefectDevelopmentDiseaseEnsureEnvironmental Risk FactorEpigenetic ProcessEtiologyExonsFlow CytometryFutureGene ExpressionGenesGenetic Predisposition to DiseaseGenetic TranscriptionGoalsHealthHumanImmuneImmune ToleranceInvestigationKnowledgeLeadLinkLoxP-flanked alleleMature B-LymphocyteMediatingModelingMolecularMusMutant Strains MiceMutateMutationPathogenesisPatientsPhenotypeProteinsRegulator GenesReportingResearchResearch DesignRoleSerumSignal PathwaySignal TransductionSpecificitySymptomsSystemTNFSF5 geneTestingUnited StatesZinc Fingersautoreactive B cellautoreactivitycell typecentral tolerancechronic autoimmune diseaseclinically relevantepigenetic regulationgene repressiongenetic variantgenome wide association studygenomic locusimprovedin vivoinsightmouse modelmutantmutant mouse modelnovelpreventprogramspublic health relevanceresponsetargeted treatmenttooltranscription factortranscriptomics
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Autoimmune diseases are chronic and often disabling illnesses that affect millions of Americans. Current
treatments help to prevent the symptoms of autoimmune disease, but there are no cures. Autoimmune disease
is thought to be due to a combination of genetic predispositions and environmental factors, but the etiology is
not fully understood. In order to develop new and improved treatments, and to potentially find a cure, a better
understanding of the underlying molecular mechanisms of autoimmune disease is essential. Using a newly
established strain of mutant mice, we found that a small targeted deletion in the gene encoding the
transcription factor Ikaros, resulted in a profound defect in immune tolerance, with high levels of autoreactive
antibodies in the serum of very young mice. Antibodies are produced by B cells, and the presence of
autoreactive antibodies indicates that Ikaros is necessary to control how B cells respond to antigen and to
ensure tolerance to self. A role for Ikaros in human autoimmune disease is supported by recent genome-wide
association studies (GWAS), where genetic variants in the Ikaros gene locus (IKZF1) have been linked to
several autoimmune diseases. Furthermore, recent studies have reported patients with autoimmune disease
that carry IKZF1 mutations. We propose to employ our Ikaros-mutant mice as a new model of autoimmunity to
investigate the molecular mechanisms underlying the break of tolerance in Ikaros-mutated B cells. We have
preliminary data suggesting that Ikaros regulates two distinct stages of B-cell maturation that are critical for
proper tolerance: The central tolerance checkpoint and the requirement for costimulatory signal upon Ag
encounter in the periphery. We will use this mouse model to directly test the hypothesis that Ikaros limits
autoreactive B cells by enforcing central tolerance and establishing a requirement for the “second signal”
(indicating danger) through epigenetic mechanisms. Accordingly, our study design is focused on an
understanding of central tolerance and B-cell autoreactivity, using a combination of in vivo and ex vivo
approaches. to directly assess the gene expression, epigenetic and signaling pathways associated with proper
versus aberrant B cell activation. Specifically, we will investigate the role of Ikaros in BCR signaling and
establishment of central tolerance (Aim 1). We will employ our Ikaros-mutant model to investigate the role of
Ikaros in the molecular mechanisms regulating mature B-cell response to antigen (Aim 2). Lastly, we will
examine the B-cell intrinsic, as well as the relative extrinsic contributions and roles of different immune cell
lineages in the observed break of B-cell tolerance (Aim 3).
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/s13104-021-05781-8
发表时间:
2021-09-20
期刊:
BMC research notes
影响因子:
1.8
作者:
[Boyd J, Rodriguez P, Schjerven H, Frietze S]
通讯作者:
Frietze S
Project 2: Bromodomains as Epigenetic Modulators of Endocrine Responsiveness in ER+ Breast Cancer
-
批准号:10608056
-
项目类别:
-
资助金额:$37.21万
-
财政年份:2021
-
负责人:Seth E Frietze
-
依托单位:
Project 2: Bromodomains as Epigenetic Modulators of Endocrine Responsiveness in ER+ Breast Cancer
-
批准号:10380072
-
项目类别:
-
资助金额:$37.26万
-
财政年份:2021
-
负责人:Seth E Frietze
-
依托单位:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
-
批准号:10410677
-
项目类别:
-
资助金额:$9.08万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Understanding Ikaros molecular functions for targeted therapies of pre-B ALL
-
批准号:10433981
-
项目类别:
-
资助金额:$35.42万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Role of the transcription factor Ikaros in development of autoimmune disease
-
批准号:10159202
-
项目类别:
-
资助金额:$45.17万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
-
批准号:9788498
-
项目类别:
-
资助金额:$47.87万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
-
批准号:10005379
-
项目类别:
-
资助金额:$48.15万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
-
批准号:10592912
-
项目类别:
-
资助金额:$1.01万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Deciphering the molecular mechanisms of histone code recognition by ATAD2/B
-
批准号:10452326
-
项目类别:
-
资助金额:$55.25万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Understanding Ikaros molecular functions for targeted therapies of pre-B ALL
-
批准号:9750657
-
项目类别:
-
资助金额:$34.95万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Understanding Ikaros molecular functions for targeted therapies of pre-B ALL
-
批准号:10203874
-
项目类别:
-
资助金额:$36.15万
-
财政年份:2018
-
负责人:Seth E Frietze
-
依托单位:
Mechanism of Ikaros Tumor Suppression in progenitor B cell leukemia
-
批准号:9178353
-
项目类别:
-
资助金额:$23.52万
-
财政年份:2016
-
负责人:Seth E Frietze
-
依托单位:
Integration and epigenetic regulation of the HHV-6 genome
-
批准号:9267933
-
项目类别:
-
资助金额:$17.24万
-
财政年份:2016
-
负责人:Seth E Frietze
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: